PEOPLE - Changes at Myriad Genetics:
This article was originally published in Clinica
Executive Summary
Salt Lake City, Utah-based Myriad Genetics, a biopharmaceutical organisation specialising in the use of proteomic and genomic technologies to create medical, diagnostic and therapeutic products, has selected John Henderson as chairman of the board. Linda Wilson has been appointed to the audit committee. Dr Henderson has been a director of Myriad since 2004, and will lead the company's commercialisation of its new Alzheimer's, cancer and AIDS-related products. Dr Wilson has been a Myriad director since 1999. Both positions arose on the death of board chairman and audit committee member Dale Stringfellow.